ABSTRACT:
Technology for messenger RNA (mRNA) was discovered as a revolutionary approach in biotechnology and medicine, particularly in vaccine development. The developing role of mRNA in therapeutic applications is examined in this article, including its use in monogenic diseases, immunosuppressive therapies, genomic editing, and cancer vaccines. The evolution of mRNA from initial discovery to its current applications showcases advancements in delivery methods, structural modifications, and immune response modulation. Recent advances have improved the efficacy and safety of mRNA treatments, including the incorporation of modified nucleosides and self-amplifying mRNA. By encapsulating genetic information that prompts immune responses without the need for live pathogens, mRNA vaccines represent a significant shift in vaccination strategies. This review discusses current methodologies, clinical trials, and future prospects for mRNA technology across various medical fields.
Cite this article:
Razi ur Rahman M, Monica P. mRNA Vaccines: A Transformative Technology with Applications Beyond. Research Journal Pharmacy and Technology. 2026;19(3):1390-4. doi: 10.52711/0974-360X.2026.00200
Cite(Electronic):
Razi ur Rahman M, Monica P. mRNA Vaccines: A Transformative Technology with Applications Beyond. Research Journal Pharmacy and Technology. 2026;19(3):1390-4. doi: 10.52711/0974-360X.2026.00200 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-3-61
REFERENCES:
1. Chaudhary, N., Weissman, D. and Whitehead, K.A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov 20, 817–838 (2021). https://doi.org/10.1038/s41573-021-00283-5
2. Son S, Lee K. Development of mRNA Vaccines/Therapeutics and Their Delivery System. Mol Cells. 2023 Jan 31; 46(1): 41-47. https://doi.org/10.14348/molcells.2023.2165
3. Hamideh Parhiz, Elena N Atochina-Vasserman, Drew Weissman. mRNA-based therapeutics: looking beyond COVID-19 vaccines, The Lancet, Volume 403, Issue 10432, 2024; 1192-1204, ISSN 0140-6736, https://doi.org/10.1016/S0140-6736(23)02444-3
4. Geall AJ, Mandl CW, Ulmer JB. RNA: The new revolution in nucleic acid vaccines. Semin Immunol. 2013; 25(2): 152–9. https://doi.org/10.1016/j.smim.2013.05.001
5. Overmars I, Au-Yeung G, Nolan TM, Steer AC. mRNA vaccines: a transformative technology with applications beyond COVID-19. Med J Aust. 2022 Jul 18; 217(2): 71-75. https://doi.org/10.5694/mja2.51620
6. Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine. 2021; 39(16): 2190–200. https://doi.org/10.1016/j.vaccine.2021.03.038
7. Antony Justin, Chennu Manisha, Tenzin Choephel, Peet Thomas, Victoria, Jeyarani, Sayani Banerjee, Sunil Mani. Recent advances in the treatment of Alzheimer’s disease: An Immunotherapeutic approach. RJPT. [cited 2025 Feb 14]. https://rjptonline.org/AbstractView.aspx?PID=2020-13-4-80
8. Lorentzen CL, Haanen JB, Met O, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022 Oct; 23(10): e450 e458. https://doi.org/10.1016/S1470-2045(22)00372-2
9. Giulietta Maruggi, Cuiling Zhang, Junwei Li, Jeffrey B. Ulmer, Dong Yu, mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases, Molecular Therapy, Volume 27, Issue 4, 2019, Pages 757-772, ISSN 1525-0016, https://doi.org/10.1016/j.ymthe.2019.01.020.
10. Linares-Fernández, S., Lacroix, C., Exposito, J. Y., and Verrier, B. (2020). Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response. Trends in Molecular Medicine, 26(3), 311–323. https://doi.org/10.1016/j.molmed.2019.10.002
11. Pollard, C., De Koker, S., Saelens, X., Vanham, G., and Grooten, J. (2013). Challenges and advances towards the rational design of mRNA vaccines. Trends in molecular medicine, 19(12), 705–713. https://doi.org/10.1016/j.molmed.2013.09.002
12. Sen A, Kumar K, Khan S, Pathak P, Singh A. Current Therapy in Cancer: Advances, Challenges, and Future Directions. Asian J Nurs Educ Res. 2024; 14(1): 77–84. https://doi.org/10.52711/2349-2996.2024.00016
13. Sonenberg, N., and Gingras, A. C. (1998). The mRNA 5' cap-binding protein eIF4E and control of cell growth. Current opinion in cell Biology, 10(2), 268–275. https://doi.org/10.1016/s0955-0674(98)80150-6
14. PM.Patil, PD Chaudhari, Megha Sahu , NJ Duragkar. Review Article on Gene Therapy. Research J. Pharmacology and Pharmacodynamics. 2012; 4(2): 77-83. https://rjppd.org/AbstractView.aspx?PID=2012-4-2-13
15. Pavan Konde, Rahul Game, Mayuri Urhe, Akanksha Shinde. Immunity Management Post Cancer Therapy. Asian Journal of Pharmaceutical Research. 2022; 12(1): 24-8. doi: 10.52711/2231-5691.2022.00005 https://doi.org/10.52711/2231-5691.2022.00005
16. Alok Kumar, Kanchan Singh, Kartik Kumar, Sachin Kumar, Arjun Singh. Immunotherapy in Cancer Treatment: Harnessing the Power of the Immune System. Research Journal of Pharmaceutical Dosage Forms and Technology. 2024; 16(1): 107-2. doi: 10.52711/0975-4377.2024.00017.
17. Sahin, U., Karikó, K., and Tureci, O. (2014). mRNA-based therapeutics--developing a new class of drugs. Nature reviews. Drug discovery, 13(10), 759–780. https://doi.org/10.1038/nrd4278
18. Tusup, M., French, L. E., De Matos, M., Gatfield, D., Kundig, T., and Pascolo, S. (2019). Design of in vitro Transcribed mRNA Vectors for Research and Therapy. Chimia, 73(5), 391–394. https://doi.org/10.2533/chimia.2019.391
19. Kumar A, Singh K, Kumar K, Singh A, Tripathi A, Tiwari L. Drug Resistance in Cancer Therapy: Mechanisms, Challenges and Strategies. Asian J Nurs Educ Res. 2024; 14(1): 95–100. https://doi.org/10.52711/2349-2996.2024.0016
20. Yisraeli, J. K., and Melton, D. A. (1989). Synthesis of long, capped transcripts in vitro by SP6 and T7 RNA polymerases. Methods in enzymology, 180, 42–50. https://doi.org/10.1016/0076-6879(89)80090-4
21. Ramanathan, A., Robb, G. B., and Chan, S. H. (2016). mRNA capping: biological functions and applications. Nucleic Acids Research, 44(16), 7511–7526. https://doi.org/10.1093/nar/gkw551
22. Patil SM, Maske AP Sapkale GN, Kure AB. Unique Approaches to Vaccine Development Formulation and Delivery. Research J. Pharmacology and Pharmacodynamics. 2010; 2(2): 99-102.
23. Kumbhar RP, Suryawanshi SS, Patil PP, Patil SV. Opportunities and Challenges in Vaccine Development. Asian J Res Pharm Sci. 2022; 12(1): 83–7. https://doi.org/10.52711/2231-5659.2022.0013
24. Schlake, T., Thess, A., Fotin-Mleczek, M., and Kallen, K. J. (2012). Developing mRNA-vaccine technologies. RNA biology, 9(11), 1319–1330. https://doi.org/10.4161/rna.22269
25. Lundstrom K. (2016). Replicon RNA Viral Vectors as Vaccines. Vaccines, 4(4), 39. https://doi.org/10.3390/vaccines4040039
26. Beissert, T., Perkovic, M., Vogel, A., Erbar, S., Walzer, K. C., Hempel, T., Brill, S., Haefner, E., Becker, R., Türeci, Ö., and Sahin, U. (2020). A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity. Molecular therapy : the journal of the American Society of Gene Therapy, 28(1), 119–128. https://doi.org/10.1016/j.ymthe.2019.09.009
27. Singh A, Nimisha N, Singh N, Gupta R. Current Insights on Vaccines available for COVID-19 like Flu Symptoms. RJPT. 2024; 17(6): 2967–74. https://doi.org/10.52711/0974-360X.2024.00464
28. Liyana Majid, Sengamalam Radhakrishnan, Vignesh Ramachandran, Ravindran Muthukumarasamy. Review on COVID-19 Vaccines. Research Journal of Pharmacy and Technology. 2022; 15(12): 5868-4. https://doi.org/10.52711/0974-360X.2022.00990